Cell therapy

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Retrieved on: 
Tuesday, March 12, 2024
CELU, Annual, Weill Cornell Medicine, Medical device, SBMT, Congress, Dementia, Innovation Park, Brain mapping, WBMF, Multiple sclerosis, Immunotherapy, Patient, Brain, Nanotechnology, Cancer, AI, Cell therapy, Society, Neurosurgery, Regenerative medicine, Therapy, DSM-IV codes, Cell, Virtual reality, Pharmaceutical industry

FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.

Key Points: 
  • FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.
  • Dr. Hariri’s keynote, titled, “Future of Cell and Immunotherapy – Cancer to Neurodegenerative Disorders,” will address cellular immunotherapy’s broad applications beyond cancer, including its potential use in neuroinflammatory and degenerative conditions, such as multiple sclerosis and Parkinson’s disease.
  • Celularity is advancing innovative cellular therapeutics to treat a range of diseases, including neurologic diseases from brain cancer to age-related cognitive decline.
  • SBMT’s 21st Annual World Congress will take place in Los Angeles, Calif., on March 14 through 17, 2024.

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

Retrieved on: 
Friday, March 15, 2024
Biotechnology, FDA, Pharmaceutical, Health, Emory University, Multiple myeloma, BMY, Development, Survival, ASH, Disease, Oncology, Patient, FACP, Committee, EMA, Cell therapy, Bristol Myers Squibb, MD, Winship Cancer Institute, European Medicines Agency, Society, ODAC, CHMP, Food, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase 3 KarMMa-3 study, including the key secondary endpoint of overall survival.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase 3 KarMMa-3 study, including the key secondary endpoint of overall survival.
  • The recommendation from the ODAC will be considered by the FDA during its ongoing review of the supplemental Biologics License Application (sBLA) for Abecma for this patient population.
  • The FDA has not yet assigned a new target action date for review of the sBLA.
  • “With patients becoming triple-class exposed earlier in the multiple myeloma treatment paradigm, it is critical that new treatment options with the potential to improve long-term outcomes are available as early as possible,” said Sagar Lonial, MD, FACP, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University.

TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

Retrieved on: 
Thursday, March 21, 2024
Dopamine, Congress, Parkinson's disease, Regenerative medicine, Transplant, Tree, Patient, Disease, Cell therapy, Society, Neuron, Therapy, Cell, IPSC, Neurodegenerative disease, Pharmaceutical industry

BORDEAUX, France, March 21, 2024 /PRNewswire/ -- TreeFrog Therapeutics, a cell therapy development company with its lead program in Parkinson's Disease is today presenting their latest data in Parkinson's Disease, at the 23rd Congress of the Japanese Society for Regenerative Medicine, in Niigata, Japan.

Key Points: 
  • Parkinson's Disease is the second most common neurodegenerative disease, caused by the progressive loss of neurons in the midbrain and other brain regions.
  • Affecting 10 million people worldwide, it is a debilitating disease and there is an urgent unmet need as only symptomatic treatment is currently available.
  • Symptoms usually appear when between 60-80% of dopaminergic neurons are already lost, so a regenerative medicine approach that can replace these neurons holds great potential.
  • The microtissue format has many benefits, including better reproducibility and a better-quality control as batch release is based on mechanism of action relevant dopamine quantification" explains Maxime Feyeux, Chief Scientific Officer, TreeFrog Therapeutics.

TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

Retrieved on: 
Thursday, March 21, 2024
Dopamine, Congress, Parkinson's disease, Regenerative medicine, Transplant, Tree, Patient, Disease, Cell therapy, Society, Neuron, Therapy, Cell, IPSC, Neurodegenerative disease, Pharmaceutical industry

BORDEAUX, France, March 21, 2024 /PRNewswire/ -- TreeFrog Therapeutics, a cell therapy development company with its lead program in Parkinson's Disease is today presenting their latest data in Parkinson's Disease, at the 23rd Congress of the Japanese Society for Regenerative Medicine, in Niigata, Japan.

Key Points: 
  • Parkinson's Disease is the second most common neurodegenerative disease, caused by the progressive loss of neurons in the midbrain and other brain regions.
  • Affecting 10 million people worldwide, it is a debilitating disease and there is an urgent unmet need as only symptomatic treatment is currently available.
  • Symptoms usually appear when between 60-80% of dopaminergic neurons are already lost, so a regenerative medicine approach that can replace these neurons holds great potential.
  • The microtissue format has many benefits, including better reproducibility and a better-quality control as batch release is based on mechanism of action relevant dopamine quantification" explains Maxime Feyeux, Chief Scientific Officer, TreeFrog Therapeutics.

Neuropathy Action Foundation Launches White Paper on Future of Gene Therapy & Urges Innovative Policy Approaches to Ensure Patient Access

Retrieved on: 
Monday, March 4, 2024
IPN, Gene, FDA, Quality of life, Food, Diabetic neuropathy, Peripheral neuropathy, Risk, NAF, Cell therapy, Society, Leukemia, Policy, Patient

SANTA ANA, Calif., March 4, 2024 /PRNewswire/ -- The Neuropathy Action Foundation (NAF), a non-profit organization dedicated to ensuring neuropathy patients have access to the treatments necessary to improve their quality of life, today announced the release of a new white paper, "The Promise of Gene Therapy for Neuropathy and Rare Diseases." The white paper explores the transformative potential of gene therapy for neuropathy and other patients and details policy considerations to ensure equitable patient access to these revolutionary treatments.

Key Points: 
  • The white paper explores the transformative potential of gene therapy for neuropathy and other patients and details policy considerations to ensure equitable patient access to these revolutionary treatments.
  • "The promise of gene therapy is immense, particularly for patients with neuropathy and other conditions with limited or no treatment options.
  • Creating New Payment Models: Innovative payment models should offset the current exorbitant costs and uncertainties associated with gene therapy.
  • Despite its decades-long scientific foundation, gene therapy represents a shift in healthcare and the translation of gene therapy from laboratory research to clinical application remains in its infancy.

Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 6, 2024
Oncology, Health, Infectious Diseases, Hospitals, COVID-19, Pharmaceutical, Biotechnology, EPS, IPR, Compugen, Immunotherapy, Food and Drug Administration, ETR, Dow Jones Sustainability Indices, Progression-free survival, Obeldesivir, FDA, Virology, FTC, Hematology, ALL, HDV, Society, Neurotoxicity, Acquisition, HCV, Cell therapy, Acute lymphoblastic leukemia, MYR, Research, HIV, Patient, Tenofovir alafenamide, Food, Infection, Multiple myeloma, Standard of care, OS, Lymphoma, B-cell lymphoma, Table, GAAP, Docetaxel, Lung cancer, Science, Earnings per share, Investment, Liver disease, Risk, ASH, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.
  • During the fourth quarter 2023, Gilead paid cash dividends of $943 million and utilized $150 million to repurchase common stock.
  • The Liver Disease portfolio sales were $691 million in the fourth quarter 2023 and remained flat compared to the same period in 2022.
  • Cell Therapy product sales increased 11% to $466 million in the fourth quarter 2023 compared to the same period in 2022.

Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024

Retrieved on: 
Monday, February 5, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Professional Services, Other Science, Research, Medical Devices, General Health, Data Analytics, Health Technology, Science, Data Management, Multimedia, Microfluidics, Kinetics, Fraunhofer Society, BRKR, SPR, Cell therapy, Surface plasmon resonance, Thermodynamics, Bruker, Drug, Drug discovery, Exhibition, Immunology, API, Acquisition, Automation, Software, Conference

At the SLAS2024 International Conference and Exhibition , Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument.

Key Points: 
  • At the SLAS2024 International Conference and Exhibition , Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument.
  • The SPR #64 system has been engineered from the bottom up to accelerate drug discovery with increased SPR throughput, leading sensitivity and data quality.
  • View the full release here: https://www.businesswire.com/news/home/20240205314598/en/
    ‘Triceratops’ SPR #64: the all new, high-throughput multiplexing Surface Plasmon Resonance (SPR) system (Photo: Business Wire)
    The ‘Triceratops’ SPR #64 system combines highest sensitivity detection with a novel microfluidics concept, which via the perpendicular rotation of the 8-channel flow cell, now facilitates the simultaneous reading of 64 sensor spots.
  • With the ‘Triceratops’ SPR #64, Bruker is now offering drug discovery customers the highest throughput in the industry with uncompromising data quality.

TriNetX Joins CERTAINTY Project to Enhance Cancer Immunotherapy

Retrieved on: 
Wednesday, January 31, 2024
Multiple myeloma, Immunotherapy, Fraunhofer Society, Cell therapy, Machine learning, Patient, Cellular, Immunology, Data, Data collection, Medical imaging

CAMBRIDGE, Mass., Jan. 31, 2024 /PRNewswire/ -- TriNetX, LLC ("TriNetX"), the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, is proud to announce its participation in the CERTAINTY project.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 31, 2024 /PRNewswire/ -- TriNetX, LLC ("TriNetX"), the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, is proud to announce its participation in the CERTAINTY project.
  • CERTAINTY, short for CEllulaR ImmunoTherapy Avatar for personalized cancer treatment, is an international research endeavor led by the Fraunhofer Institute for Cell Therapy and Immunology IZI.
  • Bringing together a consortium of partners from academia, industry, and healthcare, this project is focused on revolutionizing cancer immunotherapy.
  • The initial focus of the CERTAINTY project is on creating a virtual twin for multiple myeloma (MM), a bone marrow malignancy.

Advanced Lateral Flow Conference 2024 Innovation Award Finalists Announced

Retrieved on: 
Tuesday, January 16, 2024
Collection, SAN, Education minister, The Economist, Saliva, Hard Rock Cafe, Immunology, Conference, Compact, Creativity, LFT, Cell therapy

SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, has announced the finalists for its 2024 Innovation Awards.

Key Points: 
  • SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, has announced the finalists for its 2024 Innovation Awards.
  • The awards will be presented at the Advanced Lateral Flow Conference (ALFC) 2024.
  • Innovation Award finalists will pitch their entries to the ALFC audience on the first day of the event (Feb. 13, 2024).
  • For more information about the Advanced Lateral Flow Conference, visit alfc2024.com.

Cellular Origins, a TTP Company, Establishes Advisory Board of Global Industry Leaders

Retrieved on: 
Tuesday, January 9, 2024
Manufacturing, Other Health, Other Science, Pharmaceutical, Research, Oncology, Medical Devices, Hospitals, Genetics, Science, Technology, Cardiology, Biotechnology, Alternative Medicine, Surgery, Health, Robotics, Other Manufacturing, Health Technology, Constellation, CMR Surgical, CGT, Therapy, Cellular, Knowledge, XDR, TTP, Cell, Acquisition, Takeda, Medtech, Advisory board, CDMO, Cell therapy, GE HealthCare, Growth, Pharmaceutical industry

Professor John Campbell is the co-founder of several cell therapy startups, including Resolution Therapeutics and Swarm Oncology.

Key Points: 
  • Professor John Campbell is the co-founder of several cell therapy startups, including Resolution Therapeutics and Swarm Oncology.
  • He brings over 30 years’ experience in the immunology and cell therapy space, with significant expertise in process development and cell therapy manufacture.
  • Dr Edwin Stone, CEO of Cellular Origins, commented: “We are looking forward to working closely with John, Matthew, Paul and Geoff.
  • I look forward to joining the team as part of the Advisory Board, where my own experience and that of my colleagues on the board will support Cellular Origins through this exciting time in their development and growth.”
    View source version on businesswire.com: https://www.businesswire.com/news/home/20240108405002/en/